-
Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement
Thursday, June 9, 2011 - 7:02am | 241Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on June 7, 2017, it received a notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, until December 5, 2011 to regain compliance with NASDAQ's $1.00 minimum bid...
-
Illumina Cuts Price of Whole-Genome Sequencing for Individuals by More than Half
Wednesday, June 8, 2011 - 4:47pm | 114Illumina, Inc. (NASDAQ: ILMN) today announced a series of measures to increase access to genetic information by individuals and physicians who participate in the company's Individual Genome Sequencing service. In his remarks at the 3rd annual Consumer Genetics Show in Boston, Illumina President...
-
Benzinga's Top Pre-Market NASDAQ Gainers
Wednesday, June 8, 2011 - 8:15am | 144Cytori Therapeutics Inc (NASDAQ: CYTX) shares advanced 15.32% to $5.87 in the pre-market session. CYTX announced sustained benefits at 18 months in cardiac cell therapy heart attack trial. Ulta Salon, Cosmetics & Fragrance, Inc (NASDAQ: ULTA) shares advanced 13.73% to $56.42 in the pre-market...
-
J.P. Morgan Reiterates Overweight on Nektar Therapeutics
Wednesday, June 8, 2011 - 8:07am | 114J.P. Morgan is out with its report today on Nektar Therapeutics (NASDAQ: NKTR), reiterating Overweight. In a note to clients, J.P. Morgan writes, "We have an OW rating on NKTR as we see it as an attractive long term biotech holding. Our view is based the potential of the company to leverage its...
-
J.P. Morgan Maintains Neutral on Exelixis
Wednesday, June 8, 2011 - 7:33am | 136J.P. Morgan is out with its report today on Exelexis (NASDAQ: EXEL), maintaining Neutral. In a note to clients, J.P. Morgan writes, "We are maintaining our Neutral rating on EXEL following a tumultuous ASCO meeting. On the positive side, we are increasingly impressed by the striking bone met...
-
Top Percentage Gainers and Losers as of 2pm 06/07/11
Tuesday, June 7, 2011 - 2:27pm | 642Best 1) Temple-Inland (NYSE: TIN): Trading up 41.3% from yesterday's close to $29.67. International Paper put in a bid to acquire Temple-Inland for $30.60 per share. Temple's board rejected the deal, saying that the bid undervalued the company. 2) Westinghouse Solar (NASDAQ: WEST): Trading up 28...
-
Top Percentage Gainers and Losers as of 12pm 06/07/11
Tuesday, June 7, 2011 - 12:00pm | 515Best 1) Temple-Inland (NYSE: TIN): Trading up 39.8% from yesterday's close to $29.37. International Paper (NYSE: IP) put in a bid to acquire Temple-Inland for $30.60 per share. Temple's board rejected the deal, saying that the bid undervalued the company. 2) Westinghouse Solar (NASDAQ: WEST):...
-
Earlier, Sequenom Announces Publication of Study Manuscript on Noninvasive Detection of Fetal RHD Genotyping in Maternal Plasma
Tuesday, June 7, 2011 - 9:13am | 262Earlier, Sequenom (NASDAQ: SQNM) today announced the acceptance for publication of the manuscript titled, "Fetal RHD Genotype Detection from Circulating Cell-Free Fetal DNA in Maternal Plasma in Non-Sensitized RhD Negative Women." The article is currently available online and will appear in the...
-
Nektar Therapeutics' NKTR-181 Achieved Long-acting Pk Profile With Analgesic Response And Excellent Safety Profile
Tuesday, June 7, 2011 - 9:02am | 273Nektar Therapeutics (NASDAQ: NKTR) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate. Interim study results show that the molecule achieved its study objectives with an extended PK profile...
-
Piper Jaffray Reports ASCO Presentation From EXEL
Tuesday, June 7, 2011 - 7:42am | 123Piper Jaffray is maintaining its Overweight rating and its $13 price target on Exelixis Inc. (NASDAQ: EXEL) in light of the company's presentation at the American Society Of Clinical Oncology conference. According to Piper Jaffray, “Exelixis presented updated Cabozantinib (XL184) data in 3 oral...
-
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROE
Tuesday, June 7, 2011 - 1:41am | 139Below are the top small-cap diagnostic substances stocks on the NYSE, the NASDAQ and the AMEX in terms of return on equity. The trailing-twelve-month return on equity at Trinity Biotech plc (NASDAQ: TRIB) is 53.87%. TRIB's PEG ratio is 0.94. The trailing-twelve-month return on equity at Accelr8...
-
Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
Monday, June 6, 2011 - 2:26pm | 291Exelixis, Inc. (NASDAQ: EXEL) today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT). The data provide additional...
-
Kendle International Commences $142.5M Tender Offer and Consent Solicitation For Convertible Notes
Monday, June 6, 2011 - 9:06am | 170Kendle (Nasdaq: KNDL) today announced it is commencing a cash tender offer and consent solicitation for any and all of its $142.5 million aggregate principal amount of outstanding 3.375 percent Convertible Senior Notes due 2012. The tender offer and consent solicitation is being conducted in...
-
Waters Corporation and PREMIER Biosoft International Announce Collaboration for Advancing Lipidomics Research
Monday, June 6, 2011 - 8:32am | 226Waters Corporation (NYSE: WAT) today announced it has entered into a non-exclusive co-marketing and reselling agreement with PREMIER Biosoft International (Palo Alto, CA) to advance lipidomics research. Waters will offer PREMIER Biosoft's SimLipid® informatics platform for sale with Waters® ACQUITY...
-
JP Morgan Reports on Thermo Fisher Scientific
Monday, June 6, 2011 - 8:28am | 170JP Morgan commented on Thermo Fisher Scientific (NYSE: TMO) in a report released today. In the report, JP Morgan was positive in its assessment of the company. JP Morgan writes, "In an effort to better understand the market opportunity for Phadia, Thermo's recent $3.5B acquisition (announced on 5...